TOP TEN perturbations for Q9NQG7 (Homo sapiens)

Organism: Homo sapiens
Gene: Q9NQG7
Selected probe(set): 218402_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9NQG7 (218402_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample

Relative Expression (log2-ratio):3.1556835
Number of Samples:58 / 74
Experimental precursor-B-ALL study 1 (t(12;21)(p12,q22))
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):3.0311928
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 2 (MLL-rearranged) / precursor-B-ALL study 2 (E2A-PBX1)

Relative Expression (log2-ratio):-2.8942566
Number of Samples:4 / 2
Experimental precursor-B-ALL study 2 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (hyperdiploid)

Relative Expression (log2-ratio):2.6574545
Number of Samples:2 / 27
Experimental precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control precursor-B-ALL study 2 (hyperdiploid)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG).

precursor-B-ALL study 2 (E2A-PBX1) / T-ALL study 2

Relative Expression (log2-ratio):2.5735636
Number of Samples:2 / 13
Experimental precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control T-ALL study 2
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

c-ALL/pre-B-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):2.4447632
Number of Samples:233 / 74
Experimental c-ALL/pre-B-ALL study 1
Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 2 (MLL-rearranged) / precursor-B-ALL study 2 (TEL-AML1)

Relative Expression (log2-ratio):-2.2966423
Number of Samples:4 / 21
Experimental precursor-B-ALL study 2 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control precursor-B-ALL study 2 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG).

c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11)) / normal bone marrow sample

Relative Expression (log2-ratio):2.1656637
Number of Samples:121 / 74
Experimental c-ALL/pre-B-ALL study 1 (t(9;22)(q34,q11))
Bone marrow samples of patients with c-ALL/pre-B-ALL (t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 3 (E2A-PBX1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):2.1231546
Number of Samples:6 / 5
Experimental precursor-B-ALL study 3 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (TEL-AML1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):2.0909443
Number of Samples:15 / 5
Experimental precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).